Update shared on 30 Nov 2025
Galliford Try Holdings’ analyst price target remains unchanged at £5.98 as analysts cite steady fundamentals and only a slight uptick in the discount rate. This reflects cautious optimism in the company’s ongoing outlook.
Analyst Commentary
Analysts have expressed a mix of optimism and caution in their recent assessments of Galliford Try Holdings' outlook. Their evaluations reflect key considerations around the company’s valuation, growth prospects, and near-term execution risks.
Bullish Takeaways
- Bullish analysts highlight the steady fundamentals, indicating that core operations are expected to remain stable in the coming quarters.
- The current unchanged price target is seen as supportive. This suggests that analysts anticipate the stock will maintain its value in the medium term.
- There is confidence that disciplined cost management will continue to support profit margins. This approach may help drive consistent long-term returns.
- Modest adjustments to the discount rate are interpreted as a reflection of ongoing business resilience and manageable risks in the company’s operating environment.
Bearish Takeaways
- Bearish analysts remain wary about the company’s ability to deliver accelerated growth, given prevailing market conditions.
- There are concerns that the room for substantial upside in the valuation is limited without strong near-term catalysts.
- Potential project delays or cost overruns are seen as risks that could affect earnings and investor sentiment.
- While minor, recent increases in discount rates could signal intensifying competitive or macroeconomic pressures. These factors may temper future optimism.
What's in the News
- Appointed to a EUR 3 billion affordable homes framework by The Hyde Group. This appointment covers all seven lots across the East, South, and London regions, targeting 1,500 homes per year over five years (Client Announcement).
- Added as a constituent to the FTSE 250, FTSE 350, and FTSE 350 (Ex Investment Companies) Indexes (Index Constituent Adds).
- The board authorized a share buyback plan, with a program to repurchase up to £10 million of its own shares to enhance earnings per share and return funds to exiting shareholders. All repurchased shares will be cancelled (Buyback Transaction Announcement).
- Directors propose a final dividend of 13.5 pence per share for the 2025 financial year, raising the total dividend for the year to 19.0 pence per share. This proposal is subject to shareholder approval at the AGM on 13 November 2025 (Dividend Increase Announcement).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at £5.98, reflecting continued confidence in Galliford Try Holdings’ fair value assessment.
- Discount Rate has risen slightly from 8.98% to 9.03%, signaling a modest reassessment of risk within the current environment.
- Revenue Growth estimates are virtually unchanged and are holding steady at approximately 2.76%.
- Net Profit Margin projection is stable with no meaningful change, remaining at just above 2.01%.
- Future P/E ratio is little changed, moving marginally from 17.96x to 17.98x, suggesting only minimal adjustment in valuation expectations.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
